Cytori Therapeutics to Voluntarily Delist From the Frankfurt Stock Exchange to Consolidate Trading on the NASDAQ Global Market; Move in Response to Shift in Volume toward NASDAQ.

SAN DIEGO -- Cytori Therapeutics (NASDAQ: CYTX) (Frankfurt: XMPA) is voluntarily delisting from the Frankfurt Stock Exchange (FSE). The move is primarily in response to the significant shift in trading volume since December 2005 from the FSE toward the NASDAQ Global Market, where Cytori will maintain its primary listing. Cytori's last day of trading on the FSE will be September 25, 2007. Following this date, shares owned in Germany, the United States, or elsewhere may continue to be traded through the NASDAQ Global Market under the symbol CYTX.

"This is an opportunity to consolidate trading on one of the most efficient international stock markets, the NASDAQ Global Market, where the vast majority of our shares now trade, while simultaneously reducing redundant fees and expenses associated with a dual listing," said Mark Saad, Chief Financial Officer for Cytori. "All our shareholders will be optimally supported by the single listing and the European investment community will continue to be a priority for us, given our global reach as a regenerative medicine company."

Investors, brokers and other shareholder representatives are encouraged to contact Cytori's investor relations department directly with any questions at 858-458-0900.

Cytori Therapeutics

Cytori Therapeutics is developing and seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions. To provide these therapies, physicians remove a small amount of a patient's fat, also known as adipose tissue, and run it through Cytori's Celution[TM] System. This System quickly separates and concentrates stem and regenerative cells from adipose tissue so they may be quickly administered back to the patient about an hour later. This system will dramatically improve the way in which personalized cell-based therapies can be delivered to patients. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.